Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$0.6105
Market cap
$14.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.54
Enterprise value
$41.35M
ProPhase Labs is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements. The Company is engaged in the research, development, manufacture,
Highlights
The company's gross margin has shrunk by 166% YoY
The net income has dropped by 165% year-on-year and by 5% since the previous quarter
Key stats
What are the main financial stats of PRPH
Market
Valuations
Earnings
Shares outstanding
23.87M
Market cap
$14.58M
Enterprise value
$41.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.31
Price to sales (P/S)
0.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.24
Revenue
$12.75M
Gross profit
-$4.13M
Net income
-$27.76M
EBIT
-$35.22M
EBITDA
-$27.25M
Free cash flow
-$16.36M
Per share
Balance sheet
Liquidity
EPS
-$1.54
EPS diluted
-$1.54
Free cash flow per share
-$0.86
Book value per share
$2
Revenue per share
$0.67
TBVPS
$3.99
Total assets
$91.81M
Total liabilities
$53.68M
Debt
$27.87M
Equity
$38.13M
Working capital
$13.54M
Debt to equity
0.73
Current ratio
1.47
Quick ratio
1.14
Net debt/EBITDA
-0.98
Margins
Efficiency
Dividend
EBITDA margin
-213.7%
Gross margin
-32.4%
Net margin
-217.6%
Operating margin
-277.8%
Return on assets
-30.2%
Return on equity
-62.9%
Return on invested capital
-48.3%
Return on capital employed
-55.8%
Return on sales
-276.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRPH stock price
How has the ProPhase Labs stock price performed over time
Intraday
-6.52%
1 week
-6.22%
1 month
-20.2%
1 year
-86.46%
YTD
-86.49%
QTD
-74.77%
Financial performance
How have ProPhase Labs's revenue and profit performed over time
Revenue
$12.75M
Gross profit
-$4.13M
Operating income
-$35.43M
Net income
-$27.76M
Gross margin
-32.4%
Net margin
-217.6%
The company's gross margin has shrunk by 166% YoY
The net income has dropped by 165% year-on-year and by 5% since the previous quarter
The gross profit has plunged by 152% from the previous quarter and by 114% YoY
The operating income has shrunk by 129% YoY and by 4.3% QoQ
Growth
What is ProPhase Labs's growth rate over time
Valuation
What is ProPhase Labs stock price valuation
P/E
N/A
P/B
0.31
P/S
0.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.24
The EPS has plunged by 144% YoY and by 3.4% from the previous quarter
PRPH's price to book (P/B) is 88% lower than its 5-year quarterly average of 2.5 and 83% lower than its last 4 quarters average of 1.8
ProPhase Labs's equity has decreased by 32% YoY and by 13% QoQ
PRPH's revenue has dropped by 80% year-on-year and by 29% since the previous quarter
The P/S is 74% lower than the last 4 quarters average of 3.5 and 64% lower than the 5-year quarterly average of 2.5
Efficiency
How efficient is ProPhase Labs business performance
ProPhase Labs's return on assets has shrunk by 163% YoY and by 6% QoQ
The return on invested capital has dropped by 106% year-on-year and by 4.5% since the previous quarter
The ROS has decreased by 47% from the previous quarter
PRPH's return on equity is down by 16% since the previous quarter
Dividends
What is PRPH's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did ProPhase Labs financials performed over time
PRPH's total assets is 71% greater than its total liabilities
The company's quick ratio has shrunk by 55% YoY and by 10% QoQ
The company's total liabilities has surged by 52% YoY and by 8% QoQ
The debt is 27% less than the equity
PRPH's debt to equity has surged by 121% year-on-year and by 20% since the previous quarter
The debt has grown by 48% YoY and by 3.9% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.